Doctors demand arrest of those involved in recent attacks on two physicians in the district
Merck says study shows COVID-19 drug causes quick reduction in virus
US drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.
Published : 6 March 2021, 06:35 AM
Updated : 6 March 2021, 06:36 AM
"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.
The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May.
Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the programme in January.
RELATED STORIES
At least seven people have died from suspected heatstroke in the country
Bangladesh has already seen five deaths from ‘heatstroke’ at the start of the summer
At least five people have died reportedly from heatstroke in two days amid searing temperatures
